Background The approval of monoclonal antibodies for prevention of migraine has
revolutionized treatment for patients. Oral preventatives are still considered first line …

Background Head-to-head comparator trials between first-line oral migraine preventatives
and the new monoclonal antibodies (mAbs) blocking the calcitonin gene-related peptide …

Calcitonin gene-related peptide (CGRP), a 37 amino-acid neuropeptide found mostly in
peptidergic sensory C-fibers, has been suggested to be implicated in the pathogenesis of …

Background and purpose New prophylactics for migraine, targeting calcitonin gene‐related
peptide (CGRP), have recently emerged. Real‐world data are important for a …

Background and purpose In the phase 3b, randomized, double‐blind, placebo‐controlled
DELIVER clinical trial, eptinezumab reduced migraine frequency and headache in adults …

Background: The optimal monoclonal antibody against calcitonin gene-related peptide
(CGRP) for adult patients with migraine has yet to be determined. Therefore, we aimed to …

Abstract The French Headache Society proposes updated French guidelines for the
management of migraine. This article presents the second part of the guidelines, which is …

Background To verify the long-term (24-week) efficacy, safety, and tolerability of
fremanezumab in real-life patients with high-frequency episodic migraine (HFEM:≥ 8 …

Background Despite high efficacy and tolerability, not all patients with chronic migraine
benefit from anti-CGRP monoclonal antibodies. We aimed to identify the clinical predictors of …

Abstract Purpose of Review To summarize available calcitonin gene-related peptide
(CGRP)-targeting therapies for migraine and discuss their use in real-world populations …